The global life science software market is expected to reach a valuation of USD 13,736 million in 2023. The key growth factors driving the market are increasing research and development, expanding biotech number and size, and increasing cost efficiencies. The overall sales of life science software are projected to grow at a robust CAGR of 7.5% between 2023 and 2033, totaling around USD 31,151.8 million by the end of 2033.
Life science is a branch of science concerned with the research of living organisms. Biology, anatomy, health sciences, medical sciences, and pharmaceutics are all fields of study in life science. In today's evolving healthcare ecosystem, life science software aids in developing comprehensive, integrated solutions to the life science industry, such as product quality, regulatory compliance, speed, cost-effectiveness, and many others.
| Data Points | Key Statistics |
|---|---|
| Life Science Software Market Size (2023) | USD 13,736 million |
| Life Science Software Market Revenue Forecast (2033) | USD 31,151.8 million |
| Life Science Software Market Growth Rate (2023 to 2033) | 7.5% CAGR |
| North America Market Share | 40.5% |
Life science software includes various tools for standardizing workflow and managing documentation to serve the biopharmaceutical, medical technology, generics, and clinical care industries. These programs allow corporations to record, store, and preserve information through images and text. Various types of life science software are available, along with drug identification and affirmation, laboratory management, clinical trial management, and medical device innovation.
Continuous technological innovations, the accessibility of big data in the life science industry, the increasing adoption of analytics techniques in clinics and hospitals as well as for sales and promotion in the pharmaceutical companies, and the burgeoning need for enhanced patient care shipment are some of the major factors driving the expansion of the life science software market.
Furthermore, factors such as an increase in the frequency of chronic diseases, massive pressure to reduce healthcare spending, and a bigger emphasis on value-based medicine all contribute to the significant growth of this market.
However, aspects such as the elevated cost of implementing life science software, complex programming, additional infrastructure, and data management costs limit the expansion of the life science software market.
Due to the elevated adoption of cutting-edge technologies and a substantial majority of investments, North America dominates the life science software market. Because of the escalating digitization of healthcare-related work processes and the presence of major healthcare firms implementing this software in these regions, North America is the leading market in the life science software market. It is expected to grow rapidly over the next decade.
The United States is the key industry in North America for life science software. The market in this region will develop faster than South America's. The demand for security, easy access to data, and productive patient information management will aid the growth of the life science software industry. North America is accounting for a market share of 40.5% of the global life science software market.
The European life science software market is expected to grow at a 9% CAGR. During the forecast period, the European life science software sector is predicted to account for the largest share of the global market. Geographically, the European life science software market accounted for a sizable share of the overall in 2020 and is anticipated to grow at a healthy rate during the forecast period.
During the forecast period, the German life science software market is expected to be a lucrative business regional market in Europe. The German market benefits from social advancements such as censuses and technological advancements such as digitization. The growing use of IoT and cloud computing is expected to boost the life science software market. Europe is accounting for a market share of 24% of the global life science software market.
The biopharmaceutical segment's life science software market share will develop significantly during the forecast period. Life science software can benefit biopharmaceutical companies by providing a global healthcare standard. It bolsters the functionalities of logistic partners and collaborates with trading partners such as contract packagers. During the forecast period, these characteristics will drive segment growth.
Manufacturers are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interests of potential buyers and create a larger customer base. For instance,
Some of the leading life science software providers include Oracle Corporation, Deloitte, SAP SE, Accelrys Software, Inc., Cegedim SA, Medidata Solution, Inc., Revitas, Inc., Veeva Systems, Inc., Model N, Inc., SAS Institute, Inc., PTC Therapeutics, Inc., TIBCO Software, Inc., and Perceptive Informatics, Inc.
These key life science software providers are adopting various strategies, such as new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc., to increase their sales and gain a competitive edge in the global life science software market. For instance,
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.5% from 2023 to 2032 |
| Expected Market Value (2023) | USD 13,736 million |
| Anticipated Forecast Value (2033) | USD 31,151.8 million |
| Base Year for Estimation | 2023 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Application, End User, Deployment, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Mexico, Brazil, Germany, Italy, UK, Spain, France, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Oracle Corporation; Deloitte; SAP SE; Accelrys Software Inc.; Cegedim SA; Medidata Solution Inc.; Revitas Inc.; Veeva Systems Inc.; Model N Inc.; SAS Institute Inc.; PTC Therapeutics Inc.; TIBCO Software Inc.; Perceptive Informatics Inc. |
| Customization | Available Upon Request |
The market in 2023 is valued at USD 13,736 million.
The market is estimated to reach USD 31,151.8 million by 2033.
The market is likely to expand at a 7.5% CAGR through 2033.
The market rose at a 6% CAGR from 2018 to 2022.
North America accounts for 40.5% of revenue in 2023.
Explore Vertical Solution Insights
Life Science Software Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
